The first Astrazeneca plc trade was made in Q2 2014. Since then Paul Tudor Jones II bought shares five more times and sold shares on six occasions. The investor completely sold their stake between Q3 2025 and Q4 2025.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for th...
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining ...
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based ...
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from th...